the swiss times
en_GB English
en_GB English de_DE German fr_FR French es_ES Spanish ar Arabic
the swiss times

Ypsomed Divests Pen Needle: Focuses on Insulin Pump Innovation

Ypsomed Divests Pen Needle: Focuses on Insulin Pump Innovation

Thu, Mar 28th 2024

Ypsomed transitions pen needle and BGM business to MTD, channeling investment into expanding Solothurn site and enhancing insulin pump solutions.

(KEYSTONE/Anthony Anex)

Ypsomed, a notable player in the healthcare sector, has divested its pen needle and glucose monitoring systems (BGMs) segment to Medical Technology and Devices S.p.A. (MTD) according to a press release.

This decision is aligned with Ypsomed’s vision to concentrate on advancing and commercialising its cutting-edge mylife Loop insulin pump solution. The transition to MTD, anticipated to finalise in summer 2024, is set to ensure a continuous supply of high-quality pen needles, catering to the global demand from insulin and hormone injectors.

In the interim, Ypsomed will continue manufacturing pen needles under a contract arrangement, facilitating a smooth transition by mid-2025. This business segment, now transitioning to MTD, recorded sales of over CHF 50 million in the fiscal year 2022/23, with a subsequent CHF 18 million in the first half of FY 2023/24.

MTD aims to enrich its portfolio with Ypsomed’s acclaimed click technology and its own 34G pen needle, envisioning expanded market reach and enhanced service to the diabetes community.

Ypsomed is set to channel over CHF 100 million into its Solothurn site over the next four years, boosting autoinjector production capabilities. This expansion will not only augment its manufacturing capacity but also introduce a new injection moulding tool shop, thereby creating numerous job opportunities.

Ypsomed assures its workforce of continued employment and is actively seeking avenues to accommodate all employees affected by the business transition within the group or through partner recruiting agencies.

Related Stories

Swiss Pension Funds Perform Well In Q1 2024
Thumbnail

6 May 2024

Swiss pension funds kick off 2024 with impressive returns, maintaining a strong financial stance despite inflation...

Bern Riots: 11 Policeman Injured & Arrests
Thumbnail

6 May 2024

Unrest at Bern's Schützenmatte results in serious accusations by the regional police chief against rioters. ...

BNP Paribas (Suisse) Announces Job Cuts
Thumbnail

3 May 2024

BNP Paribas (Suisse) to cut around 100 jobs at its Geneva location, focusing reductions in support and IT....

Sandoz Q1 Strong Start To The Year With Biosimilars Growth
Thumbnail

7 May 2024

Sandoz sees a solid financial start in 2024, with biosimilars growing 21%, contributing to a total revenue of $2.5...

Hochdorf: Shareholders To Change The Board
Thumbnail

3 May 2024

Hochdorf faces a significant board transformation as Newlat proposes six new candidates, predominantly Italian....

UBS Achieves $1.76 Billion Q1 Profit: Exceeding Expectations
Thumbnail

7 May 2024

UBS records a $1.76 billion profit in the first quarter of 2024, surpassing expectations with advances post-Credit...

Brian Keller Pre-Trail Detention Approved In Zurich
Thumbnail

6 May 2024

Zurich court approves pre-trial detention for Brian Keller, citing "risk of repetition." The 28-year-old faces charges...

Stay in Touch

Noteworthy

Swiss Bank Saving Interests Already Dropping
Noteworthy
7 May 2024

Swiss Bank Saving Interests Already Dropping

UBS Chairman Colm Kelleher Talks Capital Requirements
Noteworthy
24 April 2024

UBS Chairman Colm Kelleher Talks Capital Requirements
the swiss times
A production of UltraSwiss AG, 6340 Baar, Switzerland

Quick Links

Home Privacy GTC Contact Us About Us
Copyright © 2024 UltraSwiss AG 2024 All rights reserved